• News
  • BioTech

Shire initiates Phase 3 study for patients with rare skin disorders

Shire plc (Nasdaq: SHPG), which has a facility in San Diego, on Friday announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with epidermolysis bullosa (EB).

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!